With Inotuzumab the situation is clear - monocloal antiodies as targeted treatment is not efficient, but failure of Arbaclofen placarbil is not very ... classical. The concept of prodrug design sometimes looks too mechanistic but always rational. But to be "rational" is not enough in order to be "efficient"...
DRUG DEVELOPMENT DECONSTRUCTOR MANIFESTO: : “Tell me how you read and I'll tell you who you are.” ― Martin Heidegger
Tuesday, May 21, 2013
Targeted failure of the week. Post No 71 and 72. Arbaclofen placarbil and Inotuzumab.
With Inotuzumab the situation is clear - monocloal antiodies as targeted treatment is not efficient, but failure of Arbaclofen placarbil is not very ... classical. The concept of prodrug design sometimes looks too mechanistic but always rational. But to be "rational" is not enough in order to be "efficient"...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment